Hijacking The Messenger
Understanding Why Exosomes Are Attracting Significant Investment And Partnering Attention
Executive Summary
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
You may also be interested in...
Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Novumcella Building Exosome Expertise In Inflammatory Disorders
Tokyo-based Novumcella Inc. is progressing several still preclinical stage assets derived from academic research, with a focus on the intractable inflammatory disease area, and is looking to secure new financing and partners as it considers an IPO down the road.
Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.